<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03470155</url>
  </required_header>
  <id_info>
    <org_study_id>REFORM-MR</org_study_id>
    <nct_id>NCT03470155</nct_id>
  </id_info>
  <brief_title>Operative Mitral Valve Reconstruction in Functional mv Insufficiency With Reduced Systolic Ventricle Function</brief_title>
  <acronym>REFORM-MR</acronym>
  <official_title>Operative Mitralklappenrekonstruktion Bei Funktionellen Mitralklappenvitien Bei Reduzierter Systolischer Ventrikelfunktion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional mitral insufficiency poses a challenge with regard to the optimal time of&#xD;
      intervention, particularly because they are frequently associated with left ventricular (LV)&#xD;
      dilation and reduced LV ejection fraction (EF). The registry will document the underlying&#xD;
      pathology by using transthoracal echo cardiography (TTE) with analysis of common tenting&#xD;
      parameters. OP strategies, data and outcomes will be documented, as well as follow-up data&#xD;
      for echocardiography, quality of life and MACCE outcomes after 6 months, 1 and 2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective enrolment of all patients with mitral valve insufficiency and restricted movement&#xD;
      of leaflets during systole into a multicentric registry. Exact analysis of the underlying&#xD;
      pathology using TTE with analysis of tenting parameters. In patients without&#xD;
      contraindications, functional preoperative MRT to determine the functional reserve of&#xD;
      ventricular function. Documentation of the quality of life of the patients using the SF12&#xD;
      questionnaire before and after intervention. Documentation of follow-up data (SF12, TTE,&#xD;
      NT-pro BNP) at 6 months, 1 and 2 years. Development of operative strategies to improve&#xD;
      long-term outcomes in patients with severe LV dilation (typically accompanied by function&#xD;
      mitral insufficiency type IIIb).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>recurrent mitral valve insufficiency &gt; grade 2</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>1 year</time_frame>
    <description>major adverse cardiovascular and cerebrovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-intervention at mitral valve</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>device therapy (e. g. left ventricular auxiliary device or heart transplant) due to progressive heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular mortality</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-hospitalisation due to heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>see above</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Left Ventricular Systolic Dysfunction</condition>
  <condition>Mitral Valve Prolapse</condition>
  <arm_group>
    <arm_group_label>functional mitral insufficiency op</arm_group_label>
    <description>Patients with functional mitral insufficiency with restricted leaflet movement during systole (type IIIb Carpentier) undergoing operative reconstruction (mitral valve repair)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>mitral valve repair</intervention_name>
    <description>operative reconstruction</description>
    <arm_group_label>functional mitral insufficiency op</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients presenting at participating hospitals with mitral valve dysfunction type III b who&#xD;
        give written consent to participate in the registry&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  functional mitral valve insufficiency with reduced mobility of leaflets during systole&#xD;
             (type IIIb) - effective regurgitation orifice area &gt; 20 mm2 / regurgitant volume &gt; 30&#xD;
             ml/beat&#xD;
&#xD;
          -  left ventricular ejection fraction &lt;= 50% and /or left ventricular end-diastolic&#xD;
             diameter &gt;= 60 mm&#xD;
&#xD;
          -  tenting of the proximal and / or anterior mitral leaflets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prolaps of leaflets (type II mitral regurgitation)&#xD;
&#xD;
          -  combination intervention with aortic valve repair or replacement&#xD;
&#xD;
          -  re-operation at mitral valve&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evaldas Girdauskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitäres Herzzentrum Hamburg am UKE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christiane Pohlmann, PhD</last_name>
    <phone>+49(0)4471 85033</phone>
    <phone_ext>28</phone_ext>
    <email>christiane.pohlmann@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerstin Plate</last_name>
    <phone>+49(0)447185033</phone>
    <phone_ext>31</phone_ext>
    <email>kerstin.plate@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Kathrin Funkat, PhD</last_name>
      <email>Anne-Kathrin.Funkat@leipzig-heart.de</email>
    </contact>
    <investigator>
      <last_name>Michael Borger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Koch</last_name>
      <email>Kathleen.Koch@zentralklinik.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Kuntze, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Klinik für kardiovaskuläre Chirurgie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volkmar Falk, MD</last_name>
      <email>volkmar.falk@charite.de</email>
    </contact>
    <investigator>
      <last_name>Volkmar Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karel van Praet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Kempfert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heike Strohschnitter</last_name>
      <email>Heike.Strohschnitter@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Walther, Prof. Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Herz- und Gefäßchirurgie am UHZ am UKE</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evaldas Girdauskas, MD</last_name>
      <email>egirdauskas@web.de</email>
    </contact>
    <investigator>
      <last_name>Evaldas Girdauskas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva Harmel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonas Pausch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Simon</last_name>
      <email>simons@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Markus Krane, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>annuloplasty mitral valve</keyword>
  <keyword>reduced LV function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Mitral Valve Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no IPD will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

